Go to the page content

What we are researching

The purpose of this study is to learn about the safety and tolerability of the study medicine in people with excess body weight.

Who may participate

Each clinical trial has its own requirements for who can participate, often called eligibility criteria.  Some of the key criteria for this study are listed here.  Discuss these requirements with your study doctor to determine if you may be eligible to participate.  Additional criteria for your doctor to review can be found here NCT07566390.

This study consists of two parts:  A and B.  You will only be enrolled in one part, if you participate.

Overweight or Obesity

Part A - Have a body mass index (BMI) from 25 to 34.9

Part B - Have a body mass index (BMI) from 25 to 39.9

Current Health and Medical History

Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic, cardiovascular, gastrointestinal, or endocrinological conditions, to be confirmed by your study doctor

Age

18-55 years

Study Medicine

Part A - Single injection

Part B - Once weekly injection

Number of study visits

Part A - About 11 visits over a period of about 2 and a half months

Part B - Up to 17 visits over a period of about 3 and a half months

What to expect


If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.

Once enrolled, you will be randomly assigned to receive either the study medicine at one of up to six dose levels, an active comparator medicine, or placebo (which has no active medicine in it).  All are given as an injection under the skin.

Your participation is expected to last between 2 and 4 months, and will involve one to two overnight stays (lasting 3 to 4 nights), depending on which part of the study you participate in.  All outpatient visits will occur every 1 to 7 days.  Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.

Interested in this Clinical Trial?

Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8150

You may also choose to discuss this clinical trial with your healthcare provider.